Compositions comprising bacterial strains

Patent metadata

Field	Value
Publication number	US-9839655-B2
Application number	US-201615357850-A
Country	US
Kind code	B2
Filing date	Nov 21, 2016
Priority date	Nov 20, 2015
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

First claim

What is claimed is:

1. A pharmaceutical composition that comprises:
a therapeutically effective amount of a bacteria strain of the species Enterococcus gallinarum deposited under accession number NCIMB 42488; and
a pharmaceutically acceptable excipient, diluent, or carrier;
wherein said therapeutically effective amount of said bacteria strain is an amount sufficient for treating cancer in a subject, and
wherein said bacteria strain is lyophilized.

2. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable excipient, diluent, or carrier further comprises a lyoprotectant.

3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises at least one additional bacteria strain.

4. The pharmaceutical composition of claim 1 , wherein at least 50% of said bacteria strain, as measured by an amount of colony forming units (CFU), remains viable after about 1 year of storage when said pharmaceutical composition is stored in a closed container at 25° C. at 95% relative humidity.

5. The pharmaceutical composition of claim 1 , wherein said therapeutically effective amount of said bacteria strain comprises from about 1×10 6 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of said pharmaceutical composition.

6. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises a lipopolysaccharide.

7. The pharmaceutical composition of claim 1 , wherein said therapeutically effective amount is an amount effective to increase production of at least one cytokine selected from the group consisting of IL-6, TNF-α, and IL-1β.

8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated for oral delivery.

9. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises a prebiotic compound selected from the group consisting of: a fructo-oligosaccharide, a short-chain fructo-oligosaccharide, inulin, an isomalt-oligosaccharide, a transgalacto-oligosaccharide, a pectin, a xylo-oligosaccharide, a chitosan-oligosaccharide, a beta-glucan, an arable gum modified starch, a polydextrose, a D-tagatose, an acacia fiber, carob, an oat, and a citrus fiber.

10. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises an adjuvant.

Assignees

• 4D Pharma Res Ltd

Inventors

• MULDER Imke Elisabeth
• HOLT Amy Beth
• Panzica Domenico
• Mccluskey Seanin Marie

Classifications

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/09

  {Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus}, streptococcus · CPC title

• A61K31/739 Primary

  Lipopolysaccharides · CPC title

• A61P37/04

  Immunostimulants · CPC title